Haloperidol decanoate (Standard)
Haloperidol decanoate (Standard) is the analytical standard of Haloperidol decanoate. This product is intended for research and analytical applications. Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D2 receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model.
For research use only. We do not sell to patients.
- CAS No.: 74050-97-8
- Formula: C31H41ClFNO3
- Molecular Weight:530.11
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 74050-97-8
-
Molecular Weight 530.11
-
Formula C31H41ClFNO3
-
SMILES
CCCCCCCCCC(OC1(C2=CC=C(Cl)C=C2)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. R Beresford, et al. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs. 1987 Jan;33(1):31-49. [Content Brief]
[2]. Schmitz, I., et al., (2025). A single dose of haloperidol decanoate induces short-term hippocampal neuroinflammation: focus on the glial response. Pharmacological reports : PR, 77(3), 800–808. [Content Brief]
[3]. Oh-e, Y., et al., (1991). Pharmacokinetics of haloperidol decanoate in rats. Journal of pharmacobio-dynamics, 14(11), 615–622. [Content Brief]
[4]. Akiyama, K., et al., (1987). Effect of chronic administration of haloperidol (intermittently) and haloperidol-decanoate (continuously) on D2 dopamine and muscarinic cholinergic receptors and on carbachol-stimulated phosphoinositide hydrolysis in the rat striatum. The Japanese journal of psychiatry and neurology, 41(2), 311–320. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Haloperidol decanoate (Standard) Related Classifications
HY-107969R Related Classifications
Powered by Bioz